Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.72 |
| ▸ | PTP4A3 | O75365 | 8/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.57 |
| ▸ | NAT1 | P18440 | 1/20 | 0.54 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10090185 | 0.93 | PTP4A3 (0.69) | GSK3BPTP4A3MEN1POLBBLM | |
| SCHEMBL2065170 | 0.93 | PTP4A3 (0.69) | GSK3BPTP4A3MEN1POLBBLM | |
| SCHEMBL10090288 | 0.90 | PTP4A3 (0.64) | GSK3BPTP4A3MEN1POLBBLM | |
| SCHEMBL2066176 | 0.89 | PTP4A3 (0.77) | GSK3BPTP4A3MEN1POLBBLM | |
| SCHEMBL2066177 | 0.89 | PTP4A3 (0.77) | GSK3BPTP4A3MEN1POLBBLM | |
| SCHEMBL10090290 | 0.89 | PTP4A3 (0.77) | GSK3BPTP4A3MEN1POLBBLM | |
| SCHEMBL10090289 | 0.89 | PTP4A3 (0.64) | GSK3BPTP4A3MEN1POLBBLM | |
| SCHEMBL884138 | 0.89 | PTP4A3 (0.64) | GSK3BPTP4A3MEN1POLBBLM | |
| SCHEMBL20005836 | 0.88 | GSK3B (0.72) | GSK3BPTP4A3MEN1POLBBLM | |
| SCHEMBL18102852 | 0.88 | GSK3B (0.72) | GSK3BPTP4A3MEN1POLBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206412-B2 | Thioxothiazolidine inhibitors | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2015-12-08 | — | — | US | disclosed |
| US-8357701-B2 | Galactokinase inhibitors | UNIVERSITY OF MIAMI (US) | 2013-01-22 | — | — | US | disclosed |
| US-8357701-B2 | Galactokinase inhibitors | UNIVERSITY OF MIAMI (US) | 2013-01-22 | — | — | US | disclosed |
| US-20110251236-A1 | GALACTOKINASE INHIBITORS | UNIVERSITY OF MIAMI (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251236-A1 | GALACTOKINASE INHIBITORS | UNIVERSITY OF MIAMI (US) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251236-A1 | GALACTOKINASE INHIBITORS | GALK1, GALE, GALC | GSK3B 1122/4885PTP4A3 2630/4885MEN1 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.